YUNNAN BAIYAO(000538)2025-01-09 09:28Sales Performance - In the first half of 2024, the pharmaceutical segment achieved a revenue of 4.069 billion CNY, a year-on-year increase of 9.6% [2] - Sales of the core product, Yunnan Baiyao aerosol, exceeded 1.2 billion CNY, with a growth rate of over 30% [2] - Other traditional Chinese medicine products, such as Pudi Lan anti-inflammatory tablets, surpassed 100 million CNY in sales, achieving nearly double-digit growth [3] - The sales of Gynaecological products, such as Gongxue Ning capsules, increased by 36% year-on-year [3] - The sales of Qi Xue Kang oral liquid exceeded 100 million CNY, while Sanqi Ren honey oral liquid saw a growth of over 80% [3] Marketing and Channel Strategy - The company implemented a "普药千家万户" project to enhance offline distribution and established a short-channel operation model [3] - Online marketing efforts resulted in approximately 350 million exposures and 2.96 million interactions, driving over 1.1 million consumers to e-commerce platforms [3] - The company engaged in a basketball event with 512 teams participating, generating over 290 million views on Douyin [3] Oral Care Products - Yunnan Baiyao toothpaste maintained its leading market share in the domestic oral care sector [4] - During the "618" shopping festival in 2024, Yunnan Baiyao ranked as the top oral care brand across all online platforms [4] - The company has a well-established national sales team for health products, enhancing its market competitiveness [4] Dividend Policy - In 2023, the company announced a cash dividend of 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which accounted for 90.53% of the net profit [6] - A special dividend proposal for 2024 was approved, with a distribution of 12.13 CNY per 10 shares, totaling 2.164 billion CNY, representing 50.02% of the net profit for the first three quarters [6] - Since its listing in 1993, the company has distributed over 26.6 billion CNY in cash dividends over 31 years [6] Strategic Goals - The company aims to achieve growth in revenue, profit, and asset scale through a "2+3" strategic plan from 2024 to 2028 [7][8] - The strategic positioning includes four segments: Traditional Chinese Medicine resources, pharmaceutical products, health products, and pharmaceutical commerce [7][8]